CTLA4 and immune system disorder: The prediction of the efficacy of immunotherapy with TICA and TIDE databases proved that the lower SLC7A11 level has a better curative effect of anti-PD-1/PD-L1 and anti-CTLA4 treatment and less probability of immune escape and immune dysfunction.